<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131021">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01774877</url>
  </required_header>
  <id_info>
    <org_study_id>2012BAI26B02</org_study_id>
    <nct_id>NCT01774877</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome</brief_title>
  <official_title>Efficacy and Safety of Xinfeng Capsule in the Treatment of Rheumatoid Arthritis (RA):A Randomized, Double-blind, Double-dummy, Multi-center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine</source>
  <oversight_info>
    <authority>China: Ministry of Science and Technology</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bi Syndrome is one of  Traditional Chinese Medicine（TCM）name, It means an obstruction in
      Chinese,and it refers the syndrome characterized by the obstruction of qi and blood in the
      meridians due to the invasion of external pathogenic wind,cold and dampness, manifested as
      soreness, pain, numb,etc. Bi Syndrome  contains Rheumatoid arthritis(RA). RA is a chronic
      disease affecting more than 20 million people in the world.It is one of the most common
      forms of autoimmune disease. Xin'an Medicine is one of Traditional Chinese Medicine which
      originated from AnHui. Xinfeng Capsule developed according to the Xin'an medicine theory
      ,and it has long been adopted for treatment of rheumatoid arthritis (RA). The study is aimed
      to evaluate the effectiveness and safety of Xinfeng Capsule in the treatment of RA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>ACR20  (American College of Rheumatology (ACR) criteria of 20% improvement in symptoms )</measure>
    <time_frame>baseline,week4,week8,week12</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR20 used for evaluating the efficacy of  rheumatoid arthritis (RA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR50 (American College of Rheumatology (ACR) criteria of 50% improvement in symptoms )</measure>
    <time_frame>baseline,week4,week8，week12</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR50 used for evaluating the efficacy of rheumatoid arthritis (RA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR70 (American College of Rheumatology (ACR) criteria of 70% improvement in symptoms )</measure>
    <time_frame>baseline,week4,week8，week12</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR50 used for evaluating the efficacy of rheumatoid arthritis (RA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns based on Chinese medicine(CM)symptoms</measure>
    <time_frame>baseline,week4,week8，week12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Scale (DAS)28</measure>
    <time_frame>baseline,week4,week8, week12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid arthritis (RA) biomarkers</measure>
    <time_frame>baseline, week12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Rheumatoid arthritis (RA) biomarkers,including rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) ,anti-cyclic citrullinated peptide (anti-CCP) antibodies, IgG、IgA、IgM, d-dimer, the coagulation function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality Assessment</measure>
    <time_frame>baseline,week12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Life Quality Assessment,including Health Assessment Questionnaire (HAQ), Self-rating depression scale(SDS), Self-rating anxiety scale(SAS),quality of life Questionnaire with rheumatoid arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>x-rays of the hands and wrists</measure>
    <time_frame>baseline,week12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Xinfeng capsule &amp; placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months
placebo(for leflunomide): 10 mg each time, 1 time a day, Oral,for3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>leflunomide  &amp; placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>leflunomide :10mg each time, one time a day, by mouth,for 3 months
placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xinfeng capsule</intervention_name>
    <description>Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and  NSAIDs  that they were receiving prior to study entry</description>
    <arm_group_label>Xinfeng capsule &amp; placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leflunomide</intervention_name>
    <description>leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and  NSAIDs  that they were receiving prior to study entry</description>
    <arm_group_label>leflunomide  &amp; placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA, classified by American Rheumatism Association 1987 revised criteria.

          -  According with the Zheng diagnosis of Traditional Chinese Medicine.

          -  age from 18 to 65 years.

          -  For patients currently receiving non-steroidal anti-inflammatory drugs (NSAIDs):
             Treatment at a stable dose during last 4 weeks prior to screening，or Patients do not
             take NSAIDs at least 1 weeks prior to screening.

          -  Patients not taking DMARDs at least 4 weeks prior to screening.

          -  Patients taking corticosteroids (≤15mg prednisone or Equivalent) ≥4 weeks before
             entering the trial.

          -  Patients agree to participate in this study and sign the informed consent form.

        Exclusion Criteria:

          -  Patients have received intra-articular or systemic corticosteroid injection within 4
             weeks of screening.

          -  Patients have high disease activity (DAS28-3 scores&gt; 5.1).

          -  Patients have diagnosed any other chronic inflammatory disease or connective tissue
             disease like sicca syndrome（SS）, systemic lupus erythematosus (SLE)etc;

          -  Patients with sever diseases in Cardiovascular, brain, lung, liver, kidney and
             hematopoietic system ;

          -  Patients who are pregnant or nursing mothers or Psychiatric patients.

          -  Patients with active gastroduodenal ulcer or gastritis which caused by long-term use
             of NSAIDs;

          -  The patient who has known hypersensitivity to trial medicine .

          -  Patients have participated in other clinical trials within 4 weeks of screening.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>liu jiu, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu Jian, Doctor</last_name>
    <phone>86-055162838582</phone>
    <email>liujianahzy@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first affiliated hospital of bengbu medical college</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhijun</last_name>
      <phone>86-0552-3065724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of anhui medical university</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Jianhua</last_name>
      <phone>86-0551-62922016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yijishan Hospital of Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <zip>241001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>li yan</last_name>
      <phone>86-0553-5738279</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 30, 2013</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Liu Jian</investigator_full_name>
    <investigator_title>professor，Chief Physician</investigator_title>
  </responsible_party>
  <keyword>xinfeng capsule;</keyword>
  <keyword>rheumatoid arthritis (RA);</keyword>
  <keyword>randomized;</keyword>
  <keyword>double-blind;</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
